Analyze antifibrotic therapies for metabolic dysfunction-associated steatotic liver disease (MASLD/MASH)
MASLD affects millions worldwide. It often progresses to MASH with fibrosis. Antifibrotic therapies target scar tissue buildup. They aim to reverse liver damage. Researchers focus on drugs that halt or reduce fibrosis. Recent approvals mark progress.
Resmetirom leads the pack. This THR-β agonist gained FDA approval in 2024. It treats non-cirrhotic MASH with F2-F3 fibrosis. Studies show it resolves MASH in many patients. Moreover, it improves fibrosis by at least one stage. For example, trials report 30% fibrosis regression. However, it requires daily dosing. Side effects include diarrhea. Thus, doctors monitor thyroid function closely.
Semaglutide offers another option. This GLP-1 receptor agonist won approval in 2025. It aids patients with MASH and moderate fibrosis. Phase 3 trials prove its efficacy. They demonstrate fibrosis reduction in 37% of users. In contrast, placebo helps only 22%. Semaglutide also cuts body weight significantly. Therefore, it suits obese patients. Yet, gastrointestinal issues occur often. Weekly injections improve compliance.
Lanifibranor shows promise too. This pan-PPAR agonist excels in phase 2b studies. It boosts fibrosis improvement dose-dependently. Patients see reductions in steatosis and inflammation. Additionally, it resolves MASH without worsening scars. Ongoing phase 3 trials build excitement. But, mild weight gain happens sometimes. So, experts watch metabolic profiles.
FGF21 analogues advance quickly. Efruxifermin stands out. It targets advanced fibrosis effectively. Phase 2 data reveal 39-41% fibrosis improvement. Pegozafermin follows suit. It achieves 22-27% better fibrosis scores. Efimosfermin reports 45% success rates. These drugs mimic natural hormones. They enhance metabolism and reduce scars. Nevertheless, long-term data remain limited. Injections pose a barrier for some.
Denifanstat emerges as innovative.
This fatty acid synthase inhibitor shines in trials. It leads to 41% fibrosis improvement in F2-F3 patients. It also resolves steatohepatitis well. Pemvidutide adds dual action. As a GLP-1/glucagon agonist, it shows antifibrotic effects. Phase 2 results highlight MASH resolution and scar reduction. More trials confirm its potential.
These therapies share benefits. They often combine metabolic and antifibrotic actions. For instance, weight loss aids liver health. Yet, challenges persist. High costs limit access. Not all patients respond equally. Side effects vary widely. Furthermore, advanced cirrhosis needs direct antifibrotics. Macrophage therapies develop slowly.
Future directions look bright.
Combination treatments gain traction. They target multiple pathways at once. Researchers explore biomarkers for better selection. Thus, personalized medicine grows. Ongoing trials like MAESTRO-NASH provide more data. Experts urge lifestyle changes alongside drugs.
Antifibrotic therapies transform MASLD/MASH care. They offer hope for fibrosis reversal. Patients benefit from fewer complications. Doctors choose based on stage and needs. Continued research drives innovation.